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Abstract The cyclin-dependent kinase inhibitor p57Kip2 is re-
quired for normal mouse embryonic development. p57Kip2 con-
sists of four structurally distinct domains in which the conserved
C-terminal nuclear targeting domain contains a putative Cdk
phosphorylation site (Thr342) that shares a great similitude in
the adjacent sequences with p27Kip1 but not with p21Cip1. Phos-
phorylation on Thr187 has been shown to promote degradation
of p27Kip1. Although there is sequence homology between the
C-terminal part of p27Kip1 and p57Kip2, we show that the ubiquiti-
nation and degradation of p57Kip2 are independent of Thr342. In
contrast a destabilizing element located in the N-terminal is
implicated in p57Kip2 destabilization.
- 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Proliferation is positively regulated by cyclin-dependent ki-
nases (Cdks), a family of highly regulated enzymes that link
proliferative signals with mechanical aspects of cell duplica-
tion. In opposition to Cdks are Cdk inhibitors (Ckis) that
induce cell cycle arrest in response to anti-proliferative signals,
including contact inhibition, serum deprivation [1] and cell
di¡erentiation [2^5]. Ckis can be divided in two families.
The Ink4 family includes p16Ink4a, p15Ink4b, p18Ink4c and
p19ARF. These proteins speci¢cally bind and inhibit Cdk4
and Cdk6 and not other Cdks such as Cdk2. p21Cip1,
p27Kip1 and p57Kip2, members of the other family of inhibi-
tors, the Cip/Kip family, have the ability to inhibit all G1/S
phase cyclin^Cdk complexes [6]. However, of the Ckis, only
p57Kip2 is required for embryonic development [7]. Loss of
p57Kip2 results in proliferative disorders and defects in devel-
opment of several tissues [8]. The amounts of Ckis expressed
in cells may be crucial in controlling cell cycle progression [9],
cell di¡erentiation [10] and terminally di¡erentiated cells in
mouse embryo [11]. Expression of either p57Kip2 or p21Cip1
is a requirement for muscle di¡erentiation as shown by double
knockout of p57Kip2 and p21Cip1 that gave the same muscle-
de¢cient phenotype as observed with myogenin (3/3) mice
[12]. Up-regulation of p57Kip2 has been shown to stabilize
MyoD by blocking cyclin E^Cdk2 activity [10] and by direct
interaction with MyoD [13] suggesting that a ¢ne balance
exists between cell cycle regulation and terminal di¡erentia-
tion.
The concentration of p27Kip1 is though to be regulated pre-
dominantly by posttranslational mechanisms [14,15]. p27Kip1
is degraded by both ubiquitin-independent proteolytic cleav-
age and the ubiquitin^proteasome pathway [16]. Regulation
of ubiquitin-mediated proteolysis is often achieved by phos-
phorylation of the target protein, which renders it more sus-
ceptible to degradation. p27Kip1 down-regulation is promoted
by its phosphorylation on Thr187 by the cyclin E^Cdk2 com-
plex and by various kinases such as mitogen-activated protein
kinases [17,18]. Recent data have shown that Skp2, an F-box
protein that functions as the receptor component of an SCF
(Skp1/Cul1/F-box protein) ubiquitin ligase complex, binds to
and ubiquitinates p27Kip1 only when Thr187 is phosphorylated
[19,20]. These observations indicate that phosphorylation of
p27Kip1 on Thr187 controls its stability. Because much less is
known about the role and the regulation of p57Kip2, in the
present report we have examined whether or not Thr342 in
p57Kip2 that is equivalent to Thr187 in p27Kip1 is responsible
for the accelerated degradation of p57Kip2. We show that
Thr342 is not a major phosphorylation site of p57Kip2 in
muscle cells and is not implicated in the ubiquitination and
the degradation of p57Kip2. Further analysis suggests that a
destabilizing domain in the NH2-terminal part of p57Kip2 is
implicated for its degradation.
2. Materials and methods
2.1. Cell cultures and DNA transfection
The mouse skeletal muscle cell line C2C12 was maintained in
growth medium supplemented with antibiotics and 20% fetal calf se-
rum in Dulbecco’s modi¢ed Eagle’s medium. C2C12 cells were trans-
fected by the calcium phosphate procedure as described previously [9].
2.2. Plasmids and cycloheximide treatment
For Gal4 fusion experiments, we ¢rst created an expression vector
pCMV-Gal4-HA by inserting in frame the HindIII^ClaI ¢lled in frag-
ment of Gal4 DNA binding domain at the EcoRV site of pCMV-
3HA. Gal4DBD fusion proteins were generated by PCR amplifying
cDNA encoding various domains of p57Kip2 and ligating in frame
the PCR products into pCMV-Gal4-HA. C2C12 myoblasts were
transfected with pCDNA3-HA-p57Kip2, pCDNA3-HA-p57Kip2
T342A or the various mutants in six-well plates [10]. Transfected cells
were treated with cycloheximide (Sigma) at 50 Wg/ml for the indicated
times and harvested for Western blot analyses and p57Kip2 proteins
were detected by immunoblotting [10]. K-Tubulin was used as an
internal control. Western blot were scanned and quanti¢ed by using
a GelScan (Pharmacia).
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2.3. Antibodies, immunoprecipitation and Western blot analyses
For immunoprecipitation, whole cell extracts were prepared in im-
munoprecipitation bu¡er [10]. Precleared cell lysates were incubated
with the indicated antibodies for 2^3 h at 4‡C with gentle agitation.
Immunocomplexes bound to protein G-Sepharose were then washed
several times in immunoprecipitation bu¡er. Immunoprecipitated pro-
teins were resolved by 10% SDS^PAGE. Electrophoretic transfer of
proteins from SDS^PAGE gels to nitrocellulose membranes was
blocked with Tris^HCl 50 mM, pH 7.4, 150 mM NaCl and 0.05%
Tween 20 containing 5% skimmed milk and incubated overnight at
4‡C with primary antibodies. Polyclonal (C20) anti-p57Kip2 was pro-
vided by Santa Cruz (Biotechnology, Santa Cruz, CA, USA). The
monoclonal 12CA5 anti-HA antibody was provided by Boehringer
(Mannheim, Germany) and anti-K-tubulin (clone DM1A) was sup-
plied by Sigma. Membranes were washed and incubated for 1 h
with a peroxidase-conjugated secondary antibody (Sigma). Mem-
branes were incubated with an enhanced chemiluminescence system
(ECL, Amersham) according to the manufacturer’s instructions.
2.4. Immuno£uorescence staining
Cells were cultured on coverslips and ¢xed in 2% paraformaldehyde
for 30 min at 4‡C, and permeabilized with 0.5% Triton X-100 for
5 min at room temperature. The cells were immunostained with
anti-HA antibodies (12CA5). The Texas red-conjugated F(ab/)2 frag-
ment of donkey anti-mouse IgG was used to visualize the mouse
monoclonal antibodies.
3. Results
3.1. Phosphorylation of p57Kip2 in vivo
The C-terminal domain of mouse and human p57Kip2 con-
tains a consensus Cdk phosphorylation site conserved in
p27Kip1 together with adjacent sequences (Fig. 1A). We fo-
cused on the potential role of this site in determining the
stability of p57Kip2 because phosphorylation of p27Kip1 on
Thr187 by Cdk2 is though to initiate the major pathway for
p27Kip1 proteolysis [19,20]. We generated a mammalian ex-
pression vector encoding a mutant mouse p57Kip2 protein in
which Thr342 was replaced with Ala (T342A). The phosphor-
ylation status of p57Kip2 T342A was investigated by transi-
ently expressing the HA-epitope-tagged wild-type and mutant
proteins in C2C12 cells and metabolically labeling the cells
with 32Pi. p57Kip2 proteins were then immunoprecipitated
with anti-HA and the extend of 32P incorporation was eval-
uated by autoradiography and image analysis and normalized
by the amount of p57Kip2 protein estimated by immunoblot
analysis of the immunoprecipitates with anti-p57Kip2 (Fig.
1B). The amount of 32P incorporated by the T342A mutant
was virtually identical to that incorporated by wild-type pro-
tein in C2C12 muscle cells. These results indicated that Thr342
is not a major phosphorylation site in p57Kip2. Anti-HA im-
munostaining of culture expressing HA-p57Kip2 wt and/or
p57Kip2 T342A showed identical nuclear localization of the
two proteins (Fig. 1C). Characterization of p57Kip2 levels in
the presence of cycloheximide revealed that mutation T342A
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Fig. 1. A: Alignment of the putative C-terminal Cdk phosphoryla-
tion site in mouse p27Kip1 and p57Kip2. Mutation of threonine resi-
due in alanine is in bold (T342A). B: C2C12 myoblasts (Mb) were
transfected with expression vectors encoding HA-p57Kip2 wild-type
(wt) or HA-p57Kip2 T342A. Forty-eight hours after transfection du-
plicate transfected cells were transferred in di¡erentiation medium
for 3 days (Mt). Mb and Mt were metabolically labeled with
[32P]orthophosphate for 2 h. Cells were collected and total cell ly-
sates were immunoprecipitated with anti-HA antibody. Immunopre-
cipitates were transferred onto nitrocellulose membranes. Shown is
an autoradiogram of the radioactivity incorporated into p57Kip2 and
a Western blot analysis of the same membrane probed with the
anti-p57Kip2 polyclonal antibody. C: C2C12 myoblasts were trans-
fected with mammalian expression plasmids encoding HA-p57Kip2
wt or HA-p57Kip2 T342A. Twenty-four hours later, the transfected
cells were ¢xed and immunostained with anti-HA antibody and
DAPI and examined by indirect immuno£uorescence microscopy.
D: After addition of cycloheximide to the culture medium, trans-
fected cells were harvested at various times and processed for West-
ern blot analysis of p57Kip2 proteins by using anti-HA antibody.
The decay of p57Kip2 proteins is depicted in the graph (lower pan-
el).
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did not signi¢cantly modify protein stability (Fig. 1D). Alto-
gether these data indicate that p57Kip2 T342A remained un-
a¡ected by mutation of the putative Cdk phosphorylation
site.
3.2. p57Kip2 T342A is ubiquitinated and degraded by the
proteasome in vivo
We investigated the e¡ect of di¡erent protease inhibitors on
the amount of p57Kip2 wt in asynchronous C2C12 myoblasts.
Addition of MG132 or lactacystin, two speci¢c inhibitors of
the 26S proteasome, induced an accumulation of p57Kip2 wt
protein after 4 h of treatment (Fig. 2A). In contrast, the cys-
teine protease inhibitor E64 and/or chloroquine, an inhibitor
of lysosomal proteolysis, both were ine¡ective, showing that
the proteasome pathway is mainly involved in the degradation
of p57Kip2. We next compared the e¡ects of MG132 and lac-
tacystin on the mutant p57Kip2 T342A protein level. Addition
of MG132 (Fig. 2B, lanes 2 and 5) or lactacystin (lanes 3 and
6) but not DMSO (lanes 1 and 4) induced an accumulation of
p57Kip2 T342A identical to the wild-type protein. Altogether,
these data showed that in myoblasts the proteasome pathway
degrades p57Kip2 independently of Thr342. Ubiquitination is
known to have important roles in the control of the protea-
some degradation pathway. Therefore we tested whether
p57Kip2 wt as well as mutant T342A could also be modi¢ed
by ubiquitination. Expression vectors encoding the wild-type
and the mutant T342A were cotransfected with a plasmid
encoding HA-tagged ubiquitin. Twenty-four hours after trans-
fection, C2C12 myoblasts were treated or not with MG132 for
4 h. p57Kip2 proteins were immunoprecipitated with anti-
p57Kip2 antibody from denatured cell lysates and immuno-
probed with anti-HA to detect immunoprecipitated as well
as ubiquitinated p57Kip2 proteins. In the presence of
MG132, both wild-type and the mutant T342A showed a
high degree of ubiquitination con¢rming that Thr342 is not
implicated in the ubiquitination and the degradation of
p57Kip2 (Fig. 2C).
3.3. The NH2 domain of p57Kip2 is required for rapid
proteolysis
We next asked which region of p57Kip2 is required for its
proteolysis. To do this, we constructed various p57Kip2 dele-
tion mutants either cloned in frame with the Gal4DBD (Fig.
3A) or not (Fig. 3B). We transiently expressed these deletion
mutants in C2C12 myoblasts and measured their stability.
Deletion of the amino acids 1^105 (vN1) greatly stabilized
p57Kip2 by increasing its half-life from 3 h up to 6 h. Deletion
of the COOH domain (vC1) did not a¡ect p57Kip2 stability
and deletion of the central part plus the COOH domain of
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Fig. 2. Inhibition of the proteasome activity induces p57Kip2 protein
accumulation. A: C2C12 myoblasts were transiently transfected by
an expression vector encoding HA-p57Kip2 wt. Forty-eight hours lat-
er, the level of p57Kip2 was monitored in the absence (lane 1) or in
the presence of DMSO (lane 2), the lysosomal cysteine protease in-
hibitor E64 (30 WM, lane 3), the general inhibitor of lysosomal pro-
teolysis chloroquine (100 WM, lane 4) or the proteasome inhibitors
lactacystin (10 WM, lane 5) and MG132 (50 WM, lane 6). Cell ex-
tracts were prepared and p57Kip2 accumulation was analyzed by
Western blotting. B: C2C12 myoblasts were transiently transfected
with expression vectors encoding p57Kip2 wt or p57Kip2 T342A,
treated with MG132 or lactacystin and processed as in panel A. C:
C2C12 myoblasts were transiently cotransfected with expression
plasmids encoding HA-ubiquitin, HA-p57kip2 wt or the mutant
T342A. Forty-eight hours later, transfected cells were treated for 4 h
with 20 WM MG132 (+) or not (3) before harvesting. Cells were
lysed in denaturation bu¡er containing 1% SDS, boiled for 5 min at
95‡C. The lysates were then diluted in immunoprecipitation bu¡er,
subjected to immunoprecipitation with anti-p57Kip2 antibody, and
analyzed by Western blotting with anti-HA antibodies.
1 50 100 150 200 250 300350
1
105
1
1 185
263
348
348
1051
Time (min)
Half-life
3h
>6h
3h
2h
<1h
wt
∆Ν1
∆C1
∆C2
∆C3
CKI proline rich acidic repeats QT
Gal4 HA
1 348
348105
A
B
3h
>6h
1 185
Time (min)
Half-life
1h 20
∆Ν1
∆C2
wt
0 4
5
9
0
1
8
0
2
7
0
0 4
5
9
0
1
8
0
2
7
0
Fig. 3. The NH2-terminal domain is implicated in the destabilization
of p57Kip2. A: Schematic diagram of the p57Kip2 deletion mutants
indicating the main regions of the protein, which is fused to
Gal4DBD (left panel). C2C12 myoblasts were transfected with each
indicated Gal4DBD-HA-tagged p57Kip2 mutant and cells were then
treated as in Fig. 1D. B: Expression vectors encoding HA-tagged
p57Kip2 constructs were transiently transfected in C2C12 myoblasts
and treated as in Fig. 1D.
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p57Kip2 (vC2) reduced the half-life to V2 h. On the other
hand deletion of the amino acids 106 to 348 (vC3) greatly
destabilized Gal4DBD-p57Kip2, by decreasing its half-life to
less than 1 h suggesting that the amino acids 1^105 contain
a destabilizing element. These data were con¢rmed in Fig. 3B.
This domain in p57Kip2 has been shown to contain the cyclin
and Cdk binding sites implicated in the inhibition of cyclin^
Cdk complexes [1].
4. Discussion
The phosphorylation state of many proteins a¡ects their
stability and phosphorylation of p27Kip1 on Thr187 is a central
mechanism in the control of the stability of p27Kip1 by ubiq-
uitin-mediated degradation [14^20]. Because Thr187 in p27Kip1
and Thr342 in p57Kip2 are located in a C-terminal conserved
domain (Fig. 1A), the potential role of Thr342 on p57Kip2
phosphorylation and stability was studied. Our results show
that p57Kip2 is phosphorylated in vivo and is mainly degraded
by the proteasome pathway. Mutation of Thr342 in a non-
phosphorylatable alanine residue (T342A) does not modify
the phosphorylation state nor the stability of p57Kip2 in
C2C12 muscle cells. Our data demonstrate that ubiquitination
and degradation of p57Kip2 are independent of Thr342 leading
us to the hypothesis that another posttranslational modi¢ca-
tion and/or domain in p57Kip2 is implicated in its destabiliza-
tion. This ¢nding is strengthened by the fact that p57Kip2 does
not physically interact with Skp2 (data not shown), the F-box
protein component of the SCFSkp2 implicated in the ubiquiti-
nation and the degradation of p27Kip1 phosphorylated on
Thr187 [19,20]. Posttranslational modi¢cations of target pro-
teins are implicated in the recognition by certain SCF-type E3
ubiquitin ligases and subsequent degradation by the 26S pro-
teasome. These include phosphorylation [21], proline hydrox-
ylation [22], N-glycosylation [23]. On the other hand, ubiqui-
tination of substrates requires direct binding of particular
domain(s) between the F-box protein and the substrate [24].
By using deletion and substitution mutants, we identi¢ed a
destabilizing domain in p57Kip2 protein located between ami-
no acids 1 and 105. This NH2 region contains three conserved
domains: the cyclin and Cdk binding sites and the 3-10 helix
motif. This latter has been shown to be implicated in the basis
of a molecular mechanism by which p57Kip2 but not p21Cip1
nor p27Kip1 inhibits Cdk2 kinase activity [25]. This conserved
domain in human and mouse p57Kip2 suggests that it may play
an important role in the substrate recognition. Also it may be
possible to use the powerful genetic approaches available for
yeast to identify the components involved in the p57Kip2 tar-
geting and proteolysis systems, which regulate p57Kip2 levels.
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